Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (NCT07850635) titled 'A Study of Mirdametinib in Infants and Toddlers With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Condition:
Neurofibromatosis Type 1-Associated Plexiform Neurofibromas
Intervention:
Drug: Mirdametinib
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 10, 2026
Target Sample Size: 6
...